Literature DB >> 29726617

Copy number variant analysis using genome-wide mate-pair sequencing.

James B Smadbeck1, Sarah H Johnson1, Stephanie A Smoley2, Athanasios Gaitatzes3, Travis M Drucker3, Roman M Zenka3, Farhad Kosari1, Stephen J Murphy1, Nicole Hoppman2, Umut Aypar2, William R Sukov2, Robert B Jenkins2, Hutton M Kearney2, Andrew L Feldman2, George Vasmatzis1,4.   

Abstract

Copy number variation (CNV) is a common form of structural variation detected in human genomes, occurring as both constitutional and somatic events. Cytogenetic techniques like chromosomal microarray (CMA) are widely used in analyzing CNVs. However, CMA techniques cannot resolve the full nature of these structural variations (i.e. the orientation and location of associated breakpoint junctions) and must be combined with other cytogenetic techniques, such as karyotyping or FISH, to do so. This makes the development of a next-generation sequencing (NGS) approach capable of resolving both CNVs and breakpoint junctions desirable. Mate-pair sequencing (MPseq) is a NGS technology designed to find large structural rearrangements across the entire genome. Here we present an algorithm capable of performing copy number analysis from mate-pair sequencing data. The algorithm uses a step-wise procedure involving normalization, segmentation, and classification of the sequencing data. The segmentation technique combines both read depth and discordant mate-pair reads to increase the sensitivity and resolution of CNV calls. The method is particularly suited to MPseq, which is designed to detect breakpoint junctions at high resolution. This allows for the classification step to accurately calculate copy number levels at the relatively low read depth of MPseq. Here we compare results for a series of hematological cancer samples that were tested with CMA and MPseq. We demonstrate comparable sensitivity to the state-of-the-art CMA technology, with the benefit of improved breakpoint resolution. The algorithm provides a powerful analytical tool for the analysis of MPseq results in cancer.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  bioinformatics; cancer genetics; chromosomal rearrangements; copy number variant analysis; next-generation sequencing

Mesh:

Year:  2018        PMID: 29726617      PMCID: PMC6117203          DOI: 10.1002/gcc.5

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  26 in total

Review 1.  Somatic structural variation and cancer.

Authors:  Jose M C Tubio
Journal:  Brief Funct Genomics       Date:  2015-04-21       Impact factor: 4.241

2.  Challenges for CNV interpretation in clinical molecular karyotyping: lessons learned from a 1001 sample experience.

Authors:  Karen Buysse; Barbara Delle Chiaie; Rudy Van Coster; Bart Loeys; Anne De Paepe; Geert Mortier; Frank Speleman; Björn Menten
Journal:  Eur J Med Genet       Date:  2009-09-16       Impact factor: 2.708

3.  Detecting copy number variation with mated short reads.

Authors:  Paul Medvedev; Marc Fiume; Misko Dzamba; Tim Smith; Michael Brudno
Journal:  Genome Res       Date:  2010-08-30       Impact factor: 9.043

4.  Relative impact of nucleotide and copy number variation on gene expression phenotypes.

Authors:  Barbara E Stranger; Matthew S Forrest; Mark Dunning; Catherine E Ingle; Claude Beazley; Natalie Thorne; Richard Redon; Christine P Bird; Anna de Grassi; Charles Lee; Chris Tyler-Smith; Nigel Carter; Stephen W Scherer; Simon Tavaré; Panagiotis Deloukas; Matthew E Hurles; Emmanouil T Dermitzakis
Journal:  Science       Date:  2007-02-09       Impact factor: 47.728

5.  Diverse mechanisms of somatic structural variations in human cancer genomes.

Authors:  Lixing Yang; Lovelace J Luquette; Nils Gehlenborg; Ruibin Xi; Psalm S Haseley; Chih-Heng Hsieh; Chengsheng Zhang; Xiaojia Ren; Alexei Protopopov; Lynda Chin; Raju Kucherlapati; Charles Lee; Peter J Park
Journal:  Cell       Date:  2013-05-09       Impact factor: 41.582

6.  Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer.

Authors:  Stephen J Murphy; John C Cheville; Shabnam Zarei; Sarah H Johnson; Robert A Sikkink; Farhad Kosari; Andrew L Feldman; Bruce W Eckloff; R Jeffrey Karnes; George Vasmatzis
Journal:  DNA Res       Date:  2012-09-18       Impact factor: 4.458

7.  Combined array CGH plus SNP genome analyses in a single assay for optimized clinical testing.

Authors:  Joanna Wiszniewska; Weimin Bi; Chad Shaw; Pawel Stankiewicz; Sung-Hae L Kang; Amber N Pursley; Seema Lalani; Patricia Hixson; Tomasz Gambin; Chun-hui Tsai; Hans-Georg Bock; Maria Descartes; Frank J Probst; Fernando Scaglia; Arthur L Beaudet; James R Lupski; Christine Eng; Sau Wai Cheung; Carlos Bacino; Ankita Patel
Journal:  Eur J Hum Genet       Date:  2013-05-22       Impact factor: 4.246

8.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

9.  Copy number variation detection using next generation sequencing read counts.

Authors:  Heng Wang; Dan Nettleton; Kai Ying
Journal:  BMC Bioinformatics       Date:  2014-04-14       Impact factor: 3.169

10.  Comprehensive performance comparison of high-resolution array platforms for genome-wide Copy Number Variation (CNV) analysis in humans.

Authors:  Rajini R Haraksingh; Alexej Abyzov; Alexander Eckehart Urban
Journal:  BMC Genomics       Date:  2017-04-24       Impact factor: 3.969

View more
  21 in total

1.  Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.

Authors:  Aaron S Mansfield; Tobias Peikert; James B Smadbeck; Julia B M Udell; Enrique Garcia-Rivera; Laura Elsbernd; Courtney L Erskine; Virginia P Van Keulen; Farhad Kosari; Stephen J Murphy; Hongzheng Ren; Vishnu V Serla; Janet L Schaefer Klein; Giannoula Karagouga; Faye R Harris; Carlos Sosa; Sarah H Johnson; Wendy Nevala; Svetomir N Markovic; Aaron O Bungum; Eric S Edell; Haidong Dong; John C Cheville; Marie Christine Aubry; Jin Jen; George Vasmatzis
Journal:  J Thorac Oncol       Date:  2018-10-10       Impact factor: 15.609

2.  Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group.

Authors:  Alaa Koleilat; James B Smadbeck; Cinthya J Zepeda-Mendoza; Cynthia M Williamson; Beth A Pitel; Crystal L Golden; Xinjie Xu; Patricia T Greipp; Rhett P Ketterling; Nicole L Hoppman; Jess F Peterson; Christine J Harrison; Yassmine M N Akkari; Karen D Tsuchiya; Mary Shago; Linda B Baughn
Journal:  Genes Chromosomes Cancer       Date:  2022-07-19       Impact factor: 4.263

3.  Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study.

Authors:  Cecilia Arthur; Fatemah Rezayee; Nina Mogensen; Leonie Saft; Richard Rosenquist; Magnus Nordenskjöld; Arja Harila-Saari; Emma Tham; Gisela Barbany
Journal:  Front Oncol       Date:  2022-07-05       Impact factor: 5.738

4.  Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Catherine Rehder; Lora J H Bean; David Bick; Elizabeth Chao; Wendy Chung; Soma Das; Julianne O'Daniel; Heidi Rehm; Vandana Shashi; Lisa M Vincent
Journal:  Genet Med       Date:  2021-04-29       Impact factor: 8.822

5.  Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements.

Authors:  Jess F Peterson; Beth A Pitel; Stephanie A Smoley; George Vasmatzis; James B Smadbeck; Patricia T Greipp; Rhett P Ketterling; William R Macon; Linda B Baughn
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-06-03

6.  Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy.

Authors:  Faye R Harris; Piyan Zhang; Lin Yang; Xiaonan Hou; Konstantinos Leventakos; Saravut J Weroha; George Vasmatzis; Irina V Kovtun
Journal:  Mol Oncol       Date:  2018-12-21       Impact factor: 6.603

7.  The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma.

Authors:  Neeraj Sharma; James B Smadbeck; Nadine Abdallah; Cinthya Zepeda-Mendoza; Moritz Binder; Kathryn E Pearce; Yan W Asmann; Jess F Peterson; Rhett P Ketterling; Patricia T Greipp; P Leif Bergsagel; S Vincent Rajkumar; Shaji K Kumar; Linda B Baughn
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

8.  Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer.

Authors:  Tommaso Grassi; Faye R Harris; James B Smadbeck; Stephen J Murphy; Matthew S Block; Francesco Multinu; Janet L Schaefer Klein; Piyan Zhang; Giannoula Karagouga; Minetta C Liu; Alyssa Larish; Maureen A Lemens; Marla Kay S Sommerfield; Serena Cappuccio; John C Cheville; George Vasmatzis; Andrea Mariani
Journal:  PLoS One       Date:  2021-06-10       Impact factor: 3.240

9.  Mate-pair sequencing identifies a cryptic BMPR2 mutation in hereditary pulmonary arterial hypertension.

Authors:  Sarah J Chalmers; Stephen J Murphy; Laura L Thompson; Nicole L Hoppman; James B Smadbeck; Jessica R Balcom; Faye R Harris; Robert P Frantz; George Vasmatzis; Mark E Wylam
Journal:  Pulm Circ       Date:  2021-07-12       Impact factor: 3.017

10.  Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples.

Authors:  George Vasmatzis; Xue Wang; James B Smadbeck; Stephen J Murphy; Katherine B Geiersbach; Sarah H Johnson; Athanasios G Gaitatzes; Yan W Asmann; Farhad Kosari; Mitesh J Borad; Daniel J Serie; Sarah A McLaughlin; Jennifer M Kachergus; Brian M Necela; E Aubrey Thompson
Journal:  BMC Cancer       Date:  2018-07-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.